2024
July

Delay in fibromyalgia diagnosis and its impact on the severity and outcome: a large cohort study

Fausto Salaffi

Clin Exp Rheumatol

​2024 Jun;42(6):1198-1204.

 doi: 10.55563/clinexprheumatol/ta9xtc. Epub 2024 Jul 4.

​

Abstract

75% of patients with fibromyalgia still do not get correctly diagnosed. Thus, investigators sought to assess the impact of the diagnostic delay on fibromyalgia severity.  A recent study found a delayed fibromyalgia diagnosis is linked to poorer patient outcomes, such as worsened severity.[i]  Investigators obtained data on the time to diagnosis. Participants were categorized as having an early diagnosis if their fibromyalgia was diagnosed within one year, a late diagnosis if fibromyalgia was diagnosed ≥ 1 year but ≤ 5 years, and a very late diagnosis if fibromyalgia was diagnosed ≥ 5 years after the symptoms started. 

 

The study concluded, “a significant delay in the diagnosis of fibromyalgia is associated with worse disease severity” and advised “devising diagnostic protocols for both specialists and primary care providers to facilitate timely and accurate patient evaluations.”

 

[i] Salaffi F, Farah S, Bianchi B, Lommano MG, Di Carlo M. Delay in fibromyalgia diagnosis and its impact on the severity and outcome: a large cohort study. Clin Exp Rheumatol. 2024;42(6):1198-1204. doi:10.55563/clinexprheumatol/ta9xtc

​

​

January 
Long COVID: a new word for naming fibromyalgia?
Mariette X.
Ann Rheum Dis.
2024 Jan 2;83(1):12-14.
doi: 10.1136/ard-2023-224848. PMID: 37923365.
 

Abstract

Long COVID is the name given to a syndrome comprising a wide variety of symptoms persisting more than 3 months after acute benign COVID-19, with a prevalence ranging from 10 to 80%. Symptoms are very close to fibromyalgia. Several studies showed that long COVID prevalence was much higher after the first wave of the pandemics and was associated to the fact of thinking having had COVID rather than having had really COVID. Thus, it was the stress of the first wave with the lockdown and not the consequences of the infection that probably induced this high frequency of long COVID. Numbers of studies tried to find objective biological abnormalities for explaining long COVID but none of them could be replicated and convincing. The concept of long COVID seems to be a repetition of history of medicine, in which the doctors and the society gave different names to fibromyalgia with the objective of trying to highlight the fact that fibromyalgia could be a somatic disease with a well understood pathophysiology and to avoid focusing on the psychosomatic aspects of the disease. 

In conclusion, "to name is to soothe" as said by Roland Barthes. However, "Naming things wrongly adds to the world's unhappiness" was saying Albert Camus. Thus, the term of long COVID, which suggests viral persistence of impaired immune response to the virus, is unappropriated and should be replaced by fibromyalgia-like post-COVID syndrome. Research on the psychosomatic and somatic mechanisms involved in these fibromyalgia-like post-viral syndromes must be encouraged.

TRYP THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2a CLINICAL TRIAL FOR THE TREATMENT OF FIBROMYALGIA AT THE UNIVERSITY OF MICHIGAN

EQS Newswire - Tryp Therapeutics Inc. 

KELOWNA, BC

​

Tryp Therapeutics Inc. , a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, is pleased to announce that the first patient has been dosed in a Phase 2a clinical trial being conducted by the University of Michigan in a collaboration with Tryp Therapeutics. The clinical trial is evaluating Tryp's TRP-8802 in patients with fibromyalgia.

​

Commenting on the announcement, Jim Gilligan, Tryp's Chief Scientific Officer, said, "We are excited to announce that the first person has been dosed in a clinical trial at the University of Michigan using oral psilocybin in combination with psychotherapy to explore its utility in patients with fibromyalgia. With positive results in this study, Tryp would look to continue clinical development in fibromyalgia with TRP-8803, our proprietary formulation of IV-infused psilocin, which alleviates numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. Our ultimate goal is to provide even more favorable outcomes and relief to the millions of patients currently suffering from chronic pain. Currently nearly one third of fibromyalgia patients resort to opiates at some point for pain relief."

​​

​

​

2022

​

May 2022

​

Cognitive-Behavioral and Personal Construct Therapies for Depression in Women with Fibromyalgia: A Randomized Controlled TrialCognitive-Behavioral and Personal Construct Therapies for Depression in Women with Fibromyalgia: A Randomized Controlled Study

Mari Aguilera, Clara Paz, Marta Salla, Victoria Company, Joan Carles Medina Leticia Medeiros-Ferreira, Guillem Feixas

International Journal of Clinical and Health Psychology

May​-August 2022

doi.org/10.1016/j.ijchp.2022.100296

© 2022 The Author(s). Published by Elsevier España, S.L.U.

​

​

Creative versus repetitive dance therapies to reduce the impact of fibromyalgia and pain: A systematic review and meta-analysis

Alvaro Murillo-Garcia, Jose C Adsuar, Santos Villafaina, Daniel Collado-Mateo, Narcis Gusi

Complement Ther Clin Pract

2022 May​

doi: 10.1016/j.ctcp.2022.101577

Copyright © 2022 Elsevier Ltd.

​

​

February 2022

Examination of Type D personality, depression and perceived social support in women With fibromyalgia

Aysun Özlü 1, Merve A Leblebicier 1, Gamze Ünver 2

Perspect Psychiatr Care.

2022 Feb 5.  

doi: 10.1111/ppc.13042.

Online ahead of print.

PMID: 35124812 DOI: 10.1111/ppc.13042

© 2022 Wiley Periodicals LLC.

​

Does aerobic exercise effect pain sensitisation in individuals with musculoskeletal pain? A systematic review

Lynn Tan, Flavia M Cicuttini, Jessica Fairley, Lorena Romero, Mahnuma Estee, Sultana Monira Hussain, Donna M Urquhart

BMC Musculoskelet Disord.

2022 Feb 3;23(1):113.

doi: 10.1186/s12891-022-05047-9.

PMID: 35114987   PMCID: PMC8815215   DOI: 10.1186/s12891-022-05047-9

​

​

January 2022

Effectiveness of Repetitive Transcranial Magnetic Stimulation on Managing Fibromyalgia: A Systematic Meta-Analysis

Yoo Jin Choo, Sang Gyu Kwak, Min Cheol Chang

Pain Med.

2022 Jan 4;

pnab354.  

doi: 10.1093/pm/pnab354.

Online ahead of print.

​

Assessment of retinal nerve fiber thickness and optic nerve head blood flow in female patients diagnosed with fibromyalgia syndrome

Selma Urfalioglu; Ejder Berk

Arq Bras Oftalmol​

Jan-Feb 2022;85(1):30-36.

doi: 10.5935/0004-2749.20220005.

​

​

​

2021
 

September 2021
Nondrug-based Fibromyalgia Treatment clinical trial

April 2021
A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and α2-containning GABAARs.
Li J, Zhang L, Xu C, Shen YY, Lin YH, Zhang Y, Wu HY, Chang L, Zhang YD, Chen R, Zhang ZP, Luo CX, Li F, Zhu DY.
Theranostics.
2021 Apr 3;11(12):5970-5985.
doi: 10.7150/thno.58364.
PMID: 33897893;
PMCID: PMC8058733.

Fibromyalgia revisited: do latent class analyses of symptom profiles in the general population confirm 2016 fibromyalgia diagnostic criteria?
Schmalbach B, Häuser W, Brähler E, Henningsen P, Wolfe F.
Clin Exp Rheumatol.
2021 Apr 27.
Epub ahead of print.
PMID: 33938791.

High Prevalence of Perineural Cysts in Patients with Fibromyalgia and Chronic Fatigue Syndrome
Hulens M, Bruyninckx F, Dankaerts W, Rasschaert R, De Mulder P, Stalmans I, Vansant G, Bervoets C.
Pain Med.
2021 Apr 20;22(4):883-890.
doi: 10.1093/pm/pnaa410. PMID: 33260218.

March 2021
Juvenile primary Fibromyalgia Syndrome: epidemiology, etiology, pathogenesis, clinical manifestations and diagnosis
Coles, Maya Levy et al.
Pediatric rheumatology online journal 
vol. 19,1 22.
1 Mar. 2021,
doi:10.1186/s12969-021-00493-6

A study protocol for a randomized controlled trial of an anti-inflammatory nutritional intervention in patients with fibromyalgia
Silva, Ana Rita et al.
Trials 
vol. 22 198.
9 Mar. 2021,
doi:10.1186/s13063-021-05146-3

Pain matters for central sensitization: sensory and psychological parameters in patients with fibromyalgia syndrome.
Rehm, Stefanie et al.
Pain reports
vol. 6,1 e901.
10 Mar. 2021,
doi:10.1097/PR9.0000000000000901

February 2021
Exploratory study into the relationship between the symptoms of chronic fatigue syndrome (CFS)/myalgic encephalomyelitis (ME) and fibromyalgia (FM) using a quasiexperimental design
Mckay, Pamela G et al.
BMJ open 
vol. 11,2 e041947.
1 Feb. 2021,
doi:10.1136/bmjopen-2020-041947

Altered central pain processing in fibromyalgia—A multimodal neuroimaging case-control study using arterial spin labeling
Müller, Monika et al. 
PloS one 
vol. 16,2 e0235879.
2 Feb. 2021,
doi:10.1371/journal.pone.0235879

Immediate Effects of a Telerehabilitation Program Based on Aerobic Exercise in Women with Fibromyalgia.
Hernando-Garijo, Ignacio et al.  
International journal of environmental research and public health
vol. 18,4 2075.
20 Feb. 2021,
doi:10.3390/ijerph18042075

January 2021
Alteration of Postural Balance in Patients with Fibromyalgia
Syndrome—A Systematic Review and Meta-Analysis
Núñez-Fuentes, David et al.
Diagnostics (Basel, Switzerland) 
vol. 11,1 127.
15 Jan. 2021,
doi:10.3390/diagnostics11010127

Low-Dose Dextromethorphan for the Treatment of Fibromyalgia Pain: Results from a Longitudinal, Single-Blind, Placebo-Controlled Pilot Trial
Mueller, Christina et al.
Journal of pain research 
vol. 14 189-200.
27 Jan. 2021,
doi:10.2147/JPR.S285609

Attentional function in fibromyalgia and rheumatoid arthritis
Galvez-Sánchez, Carmen M et al.
PloS one 
vol. 16,1 e0246128.
27 Jan. 2021,
doi:10.1371/journal.pone.0246128